Myostatin (GDF-8) is the chief chalone in skeletal muscle and negatively controls adult skeletal muscle growth. The role of myostatin during overload-induced hypertrophy of adult muscle is unclear. We tested the hypothesis that overloaded adult rodent skeletal muscle would result in reduced myostatin protein levels. Overload-induced hypertrophy was accomplished by unilateral tenotomy of the gastrocnemius tendon in male adult Sprague-Dawley rats followed by a two-week period of compensatory overload of the plantaris and soleus muscles. Western blot analysis was performed to evaluate changes in active, latent and precursor myostatin protein levels. Significant hypertrophy was noted in the plantaris (494 ± 29 vs. 405 ± 15 mg, p < 0.05) and soleus (289 ± 12 vs. 179 ± 37 mg, p < 0.05) muscles following overload. Overloaded soleus muscle decreased the concentration of active myostatin protein by 32.7 ± 9.4% (p < 0.01) while the myostatin precursor protein was unchanged. Overloaded plantaris muscle decreased the concentration of active myostatin protein by 28.5 ± 8.5% (p < 0.01) while myostatin precursor levels were reduced by 17.5 ± 5.9% (p < 0.05). Myostatin latent complex concentration decreased in the overloaded soleus and plantaris muscle by 15.0 ± 5.9% and 70.0 ± 2.3% (p < 0.05), respectively. These data support the hypothesis that the myostatin signaling pathway in overloaded muscles is generally downregulated and contributes to muscle hypertrophy. Plasma concentrations of total and active myostatin proteins were similar in overloaded and control animals and averaged 8865 ± 526 pg/ml and 569 ± 28 pg/ml, respectively. Tissue levels of BMP-1, an extracellular proteinase that converts myostatin to its active form, also decreased in overloaded soleus and plantaris muscles by 40.4 ± 12.9% and 32.9 ± 6.9% (p < 0.01), respectively. These data support the hypothesis that local, rather than systemic, regulation of myostatin contributes to the growth of individual muscles, and that an association exists between the extracellular matrix proteinase BMP-1 and the amount of active myostatin in overloaded muscles.

A produção de aves no Brasil vem crescendo na ordem de 10% a cada ano, o que se explica pela atualização constante da tecnologia do setor (http://www.abef.com.br). Sendo a carne de frango a fonte de proteína animal mais barata e acessível ao consumidor, há necessidade de se produzir cada vez mais animais com maior acúmulo de massa muscular. Para isso, o entendimento dos mecanismos celulares e moleculares envolvidos na formação da musculatura esquelética é de extrema relevância. Os fatores miogênicos, genes responsáveis pela determinação e diferenciação de células musculares, foram clonados e progressos significativos foram desenvolvidos quanto ao controle da expressão dos mesmos. A utilização da técnica de seqüenciamento de DNA possibilita a identificação e caracterização de novos genes envolvidos na complexa rede de fatores que regulam a formação da musculatura esquelética em aves. Neste estudo, foram construídas duas bibliotecas de cDNA (fase embrionária e pós-eclosão) de músculo peitoral de uma linhagem de corte (TT) e uma biblioteca da fase embrionária de uma linhagem de postura (CC). A análise das seqüências EST (Expressed Sequence Tags) foi utilizada para identificar possíveis novos genes envolvidos no processo de formação da musculatura esquelética. As seqüências EST identificadas possibilitaram a construção de um banco com 6247 ESTs da musculatura peitoral das linhagens de corte e postura nas duas fases de desenvolvimento. Com o intuito de estabelecer uma relação entre o perfil de expressão dos fatores miogênicos: MyoD, MRF4 e miogenina; e dos genes Pax-3 e miostatina e a formação e maturação das fibras musculares, foi utilizada a técnica de PCR em tempo real. Em geral, a expressão dos fatores miogênicos foi maior na linhagem de corte em relação à de postura nas idades estudadas. Este estudo deverá contribuir para as áreas celular e molecular de desenvolvimento, além de fornecer recursos úteis aos programas de melhoramento genético de aves que visam obter animais com maior acúmulo de massa muscular. / Brazilian’s chicken production is increasing annually around 10%, which can be explained by the current technology applied to this sector (http://www.abef.com.br). Being chicken’s meat the cheapest animal protein source for consumers, there is a need to produce even more animals with increased muscular mass. For this purpose, understanding the molecular and cellular mechanisms involved with the skeletal muscle development is of great relevance. The myogenic factors, genes responsible for the determination and differentiation of muscle cells, were cloned and significant progress was made on the control of their expression. The use of DNA sequencing technique allows the identification and characterization of new genes involved in the complex chain of factors signalling systems that regulates the expression of avian skeletal muscles. In this study, two cDNA libraries (embryonic and post-hatching phases) were constructed from the breast muscle of a chicken broiler line (TT) and one library, from the embryonic phase, from a chicken layer line (CC). The EST (Expressed Sequencing Tags) analysis was used to identify probable new genes involved in the skeletal muscle development. The identified ESTs were used to generate a database containing 6247 breast muscle ESTs from two chicken lines in two development phases. Real time PCR was employed with the aim of establishing a relationship among the expression profile of myogenic factors (MyoD, MFR4, and myogenin), Pax-3 and myostatin genes with the formation and maturation of muscle fibers. In general, the expression of myogenic factors was greater in the broiler than in the layer chicken line in the phases under study. These results should contribute to other cellular and molecular development studies besides providing useful resources for chicken breeding programs whose objective is the deposition of skeletal muscle mass.

La myopathie centronucléaire autosomique dominante (MCN-AD) est une maladie congénitale rare liée à des mutations principalement retrouvées dans le gène dynamine-2. La majorité des patients atteints de MCN-AD présente une évolution lentement progressive, avec une perte de masse et de force musculaire. A ce jour, aucune thérapie n’est disponible pour la MCN-AD. Des interventions thérapeutiques visant à limiter la progression et la sévérité de l’atteinte musculaire ainsi qu’à améliorer la qualité de vie des patients, sont donc nécessaires. Nous faisons l’hypothèse qu’une hypertrophie induite par l’invalidation de la myostatine (mstn), régulateur négatif majeur de la masse musculaire, pourrait être bénéfique pour la souris modèle de cette pathologie (KI-Dnm2R465W/+), permettant notamment le maintien de la masse et de la force musculaire. Nous avons généré un modèle doublement muté résultant du croisement de souris KI-Dnm2R465W/+ myopathe avec des souris KO-mstn hypermusclées. Notre étude démontre que l'inactivation du gène mstn permet une amélioration de la masse et du volume musculaire, limite la perte de force et de motricité. Nos données suggèrent également que cette amélioration est majoritairement due à une diminution du niveau d’expression de certains acteurs impliqués dans le système catabolique ubiquitine-protéasome. De plus, nous montrons une accélèration de la diminution de la fréquence des anomalies histologiques caractéristiques de la myopathie chez les souris KI-Dnm2R465W/+. Nous proposons que ces anomalies pourraient être dues à une altération de la structure et/ou de la fonction mitochondriale. / Autosomal dominant centronuclear myopathy (AD-CNM) is a rare congenital muscle disease caused by mutations predominantly found in the dynamin 2 gene (DNM2). The clinical features generally reported are progressive muscle atrophy and weakness. To date, no treatment is available. The mouse model for AD-CNM harboring a mutation of the dynamin-2 gene (KI-Dnm2R465W/+) reproduces some of the human clinical features, notably muscle atrophy and weakness. Mstn, is a master negative regulator of skeletal muscle mass. We hypothesized that inactivation of mstn could limit muscle atrophy and weakness reported in the AD-CNM mouse model (KI-dnm2R465W/+). To test this hypothesis, we intercrossed KI-Dnm2R465W/+ mice with mice inactivated for mstn (KO-mstn) to generate a double mutated lineage (KIKO). The present study demonstrates that mstn gene inactivation allows for an improvement of muscle weight and volume, prevents muscle weakness and motor skill alterations. Our data also reveal that inactivation of mstn essentially downregulates some actors implicated in the catabolic ubiquitin-proteasome system. Furthermore, we show that inactivation of mstn decreases the frequency of of histological abnormalities characteristical in KI mice. We hypothesize that these abnormalities could be due to an alteration of mitochondrial function and network. The perspective to this work is to verify this hypothesis in the mouse model, which will contribute to a better understanding of the physiopathological mechanisms and can open new insight in the therapeutical approach to AD-CNM.

Submitted by Ronildo Prado (ronisp@ufscar.br) on 2017-08-22T17:21:37Z No. of bitstreams: 1 TeseRNS.pdf: 3515617 bytes, checksum: 251005e22df508ed87d98457bd4a5d3d (MD5) / Approved for entry into archive by Ronildo Prado (ronisp@ufscar.br) on 2017-08-22T17:21:47Z (GMT) No. of bitstreams: 1 TeseRNS.pdf: 3515617 bytes, checksum: 251005e22df508ed87d98457bd4a5d3d (MD5) / Approved for entry into archive by Ronildo Prado (ronisp@ufscar.br) on 2017-08-22T17:21:54Z (GMT) No. of bitstreams: 1 TeseRNS.pdf: 3515617 bytes, checksum: 251005e22df508ed87d98457bd4a5d3d (MD5) / Made available in DSpace on 2017-08-22T17:22:00Z (GMT). No. of bitstreams: 1 TeseRNS.pdf: 3515617 bytes, checksum: 251005e22df508ed87d98457bd4a5d3d (MD5) Previous issue date: 2016-09-15 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Hyperammonemia impairs skeletal muscle protein synthesis and induces autophagy by upregulating myostatin via nuclear factor-kappaB (NF-kB). Skeletal muscle ammonia metabolism occurs via synthesis of glutamate and glutamine via critical TCA intermediate α-KG, that regulates increase expression of hypoxia inducible factor 1α (HIF-1α). Furthermore, there is a interaction between HIF-1α and NF-kB. Objective: This study evaluated the effects of hyperammonemia in NF-kB and HIF-1α cross-talking. Methods: To examine the effects of ammonium acetate intervention under HIF-1α signaling through NF-kB pathway it has generated a stable knockdown cell line for NFkB and the subunits α and β of the I kappa B kinase (IKK) complex (IKKα and IKKβ) evaluating the HIF-1α and myostatin activities. Results: The protein expression of HIF- 1α was significantly higher in C2C12 murine myotubes under ammonium acetate intervention compared to control. Once the deletion of NF-kB, IKKα and IKKβ occurs, the HIF-1α is not expressed, suggesting a cross-talking between them. The protein expression of myostatin was significantly higher in C2C12 IKKα deletion under ammonium acetate intervention compared to C2C12 random suggesting that myostatin is not IKKα dependent. Conclusion: We conclude that hyperammonemia is a normoxemic activator of HIF-1α through NF-kB pathway that results in sarcopenia via up-regulation of myostatin expression. / Um dos grandes mediadores de sarcopenia em cirrose é a hiperamonemia. Esta anormalidade metabólica é frequente em doenças hepáticas promovendo conversão danificada de amônia em uréia prejudicando a síntese protéica e induzindo autofagia do músculo esquelético pela up-regulação de miostatina via fator nuclear kappa B (NFkB). O metabolismo de amônia no músculo esquelético ocorre via síntese de glutamato e glutamina através do intermediário metabólico α-cetoglutarato do ciclo de Krebs, que regula o Fator Induzido por Hipóxia (HIF-1α). Além disso, existe um interação entre os dois fatores de transcrição HIF-1α and NF-kB. Objetivo: Este estudo avalia os efeitos da hiperamonemia no cross-talking entre NF-kB and HIF-1α. Métodos: Para examinar os efeitos do aumento da concentração de amônia na expressão de HIF-1α através da via NF-kB foi realizado um knockdown estável de NF-kB, e as subunidades IKKα e IKKβ do complexo I kappa B quinase (IKK) em células C2C12 avaliando as atividades de HIF- 1α e miostatina. Resultados: A expressão protéica de HIF-1α foi significativamente alta em células C2C12 sob tratamento com acetato de amônia comparado com controle. Uma vez que ocorre o silenciamento de NF-kB, IKKα and IKKβ em células C2C12, não é observada a expressão protéica de HIF-1α, sugerindo um cross-talking entre eles. A expressão protéica de miostatina foi significativamente alta em células C2C12 silenciadas para IKKα sob tratamento com acetato de amônia comparado com células C2C12 random (controle), sugerindo que miostatina não é dependente da quinase IKKα. Conclusão: Foi concluído que hiperamonemia é um ativador normóxico de HIF-1α através da via de sinalização NF-kB resultando em sarcopenia via up-regulação de miostatina.

Made available in DSpace on 2016-06-02T19:22:52Z (GMT). No. of bitstreams: 1 2703.pdf: 887815 bytes, checksum: ffe15f73632c174ed03a17b4e76bcee7 (MD5) / Universidade Federal de Sao Carlos / Androgenic-anabolic steroids (AAS) are spread among athletes and no athletes in order to improve performance or physical appearance. AAS targets the satellite cells in skeletal muscles, which are the major precursors of the skeletal muscle, and are essential for muscle growth and repair. When activated, in the presence of several factors, including myogenic differentiation factor D (MyoD), they proliferate and differentiate into new myofibers or myonuclei, resulting in increased protein synthesis. On the other hand, myostatin is able to inhibit cell cycle progression. Up-regulation of the expression of ubiquitin ligases, Atrogin-1 and muscle ring finger protein 1 (MuRF-1), results in increased muscle degradation. The understanding of AAS mechanism of action in skeletal muscle is critical for a better comprehension of muscular physiology under AAS use and abuse. The aim of this study was to investigate the effects of resistance training associated to AAS supraphysiological dose on the expression of modulators of skeletal muscle pathways of atrophy and hypertrophy. Wistar rats were grouped into: sedentary (S); trained (T); S with AAS (A); and T with AAS (TA). Exercised groups performed jumps in water: 4 sets of 10 jumps each and 30-second of rest interval between series, for 7 weeks with a progressive overload of 50 to 80% of body weight. Nandrolone decanoate (5 mg/kg) was injected sc twice a week. After last exercise session animals were killed. Myostatin, MyoD, Atrogin-1 and Murf mRNA expression were determined in the gastrocnemius muscle extracts by real-time reverse transcriptase-polimerase chain reaction (RT-PCR). The exercise did not change RNAm expression of any studied genes while AAS or its association with training increased atrogina-1 and reduced myostatin RNAm. The expression of MyoD and MuRF-1 was not altered by AAS. These results showed that both myostatin and atrogin-1, important genes of skeletal muscle related to cell cycle progression and protein degradation, are sensitive to supraphysiological doses of AAS. / O uso de esteróides anabólicos androgênicos (EAA) é disseminado entre atletas e não atletas que desejam melhorar o desempenho ou a aparência física. Os EAA agem sobre as células satélites no músculo esquelético, que são as principais precursoras do músculo esquelético, sendo essenciais tanto para crescimento quanto para reparo muscular. Quando são ativadas, na presença de diversos fatores, incluindo o fator D de diferenciação miogênica (MyoD), elas podem se proliferar e diferenciar-se em novas miofibrilas ou mionúcleos, resultando em maior síntese proteica. Por outro lado, a miostatina é capaz de inibir essa progressão do ciclo celular. Uma maior expressão de ubiquitinas de ligação, Atrogina-1 e muscle ring finger protein 1(MuRF-1), resulta em aumentada degradação muscular. Entender os mecanismos de ação dos EAA no músculo esquelético é essencial para uma melhor compreensão da fisiologia muscular sob a ação dos EAA. O objetivo desse estudo foi investigar os efeitos do treinamento pliométrico aquático com sobrecarga associado a doses suprafisiológicas de EAA sobre a expressão de moduladores de vias de hipertrofia e atrofia do músculo esquelético. Ratos Wistar foram agrupados em não treinados (S), treinados (T), S tratados com EAA (E), e T tratados com EAA (TE). Os grupos que treinaram realizaram saltos na água: quatro séries de 10 saltos com 30 segundos de intervalo entre as séries, 5 vezes por semana durante 7 semanas, com uma sobrecarga progressiva de 50 a 80% do peso corporal. Decanoato de nandrolona (5 mg/kg) foi injetado subcutaneamente duas vezes por semana. Imediatamente após a última sessão os animais foram mortos. A expressão gênica de miostatina, MyoD, Atrogina-1 e MuRF-1 do músculo gastrocnêmio foi determinada por transcriptase reversa-reação em cadeia da polimerase (RT-PCR) em tempo real. O treinamento não alterou a expressão de nenhum dos genes estudados, enquanto sua associação com o EAA aumentou a expressão gênica de atrogina-1 e reduziu de miostatina. A expressão de MyoD e MuRF-1 não foi alterada pelo EAA. Os resultados mostraram que tanto a miostatina quando a atrogina-1, importantes genes relacionados tanto a progressão do ciclo celular quanto a degradação de proteínas no músculo esquelético, são sensíveis ao EAA.

Les accidents vasculaires cérébraux (AVC) sont considérés comme la pathologie neurologique la plus sévère en termes de mortalité et d’infirmité. Ils touchent plus de 140 000 personnes chaque année. L’AVC ischémique, qui représente 80% des AVC, est causé par l’occlusion localisée d’un vaisseau conduisant à un arrêt de l’apport en oxygène et en glucose au cerveau. Il est ainsi responsable de déficits moteurs, sensitifs et cognitifs qui peuvent gravement compromettre l’autonomie et la qualité de vie des patients. Les patients qui ont subi un AVC ischémique développent notamment une atrophie musculaire qui se produit principalement dans le membre parétique, mais aussi dans une moindre mesure dans le membre non parétique. Toutefois, les mécanismes moléculaires à l’origine de cette atrophie musculaire sont méconnus. Dans une première étude, l’objectif a été d’identifier les déterminants moléculaires mis en jeu dans l’atrophie musculaire induite par une ischémie cérébrale. Pour répondre à cet objectif, les travaux ont été menés sur un modèle d'ischémie cérébrale chez la souris qui consiste en l’occlusion de l'artère cérébrale moyenne par un monofilament en nylon. Nous avons montré que l’ischémie cérébrale entraînait, 3 jours après son induction, une atrophie musculaire des muscles quadriceps, soleus et tibialis anterior du côté parétique. Cette atrophie musculaire était associée à des déficits moteurs touchant l’équilibre, la coordination, la force musculaire, la posture ou la marche. Au niveau moléculaire, nous avons reporté un déséquilibre de la balance entre la synthèse et la dégradation des protéines musculaires en faveur d’une augmentation de la dégradation dans les muscles parétique et non parétique des souris ischémiées. Nous avons notamment montré que l’expression de la myostatine, un régulateur négatif majeur de la masse musculaire, était significativement augmentée. Dans une seconde étude, l’objectif a été d’identifier une cible d’intervention thérapeutique pour préserver la masse musculaire suite à une ischémie cérébrale. Au vu des résultats obtenus dans la première étude, nous avons ciblé la myostatine. Nous avons montré que l’inhibition de la myostatine entraînait, une meilleure récupération du poids de corps et du poids de divers muscles, 15 jours après une ischémie cérébrale. De plus, l’inhibition de la myostatine tendait à améliorer le comportement moteur des souris ischémiées (équilibre, coordination, force musculaire). En revanche, nous n’avons reporté aucune variation majeure des niveaux en ARNm ou protéines d’acteurs impliqués dans les voies de signalisation Akt/mTOR, Smad2/3, ubiquitine-protéasome et autophagie-lysosome, 15 jours après une ischémie cérébrale. Ces données préliminaires suggèrent que l’inhibition pharmacologique de la myostatine pourrait représenter une stratégie thérapeutique efficace pour limiter la perte de masse musculaire suite à une ischémie cérébrale / Strokes are considered as the most severe neurological disease in terms of mortality and disability. The incidence of stroke in France is estimated at 140 000. Ischemic stroke, which represents about 80% of strokes occur as a result of an obstruction of a blood vessel supplying blood to the brain. Motor, cognitive and sensory deficits are common impacts of stroke and can seriously compromise the autonomy and patient quality of life. Ischemic stroke leads to muscle atrophy, wich occurs primarily in the paretic limb, but also to a lesser extent in the nonparetic limb. However, the molecular mechanisms of muscle atrophy is unknown. In a first study, the purpose was to identify the molecular determinants involved in skeletal muscle atrophy following cerebral ischemia. To meet this objective, the work was carried out on a mouse model of cerebral ischemia, which involves the occlusion of the middle cerebral artery (MCAO) with a nylon monofilament. We have shown that cerebral ischemia leads to skeletal muscle atrophy of quadriceps, soleus and tibialis anterior muscles of the paretic side, 3 days after MCAO. This muscular atrophy was associated with motor deficits in the balance, coordination, muscle strength, posture and walking. From a molecular point of view, we reported an imbalance between the rates of synthesis and degradation of muscle protein, in favour of protein degradation in both paretic and nonparetic muscles. In particular, we showed that the expression of myostatin, a master negative regulator of skeletal muscle mass was significantly increased. In a second study, the purpose was to identify a target for therapeutic intervention in order to maintain muscle mass following cerebral ischemia. In view of the results obtained in the first study, we targeted the myostatin. Our results show that myostatin inhibition increases body weight and muscle mass recovery, 15 days after cerebral ischemia. In addition, myostatin inhibition tends to improve motor behavior (balance, coordination, strength). From a molecular point of view, we reported no major change in mRNA or protein level of actors involved in Akt/mTOR, Smad2/3, autophagy-lysosome and ubiquitin-proteasome pathways, involved in the control of muscle mass, 15 days after cerebral ischemia. These preliminary results strongly suggest that pharmacological inhibitors of myostatin may provide significant therapeutic benefit for muscle atrophy following cerebral ischemia

La cachexie est un syndrome clinique et métabolique caractérisé par une perte de tissu adipeux et de tissu musculaire, fréquemment observé chez les patients atteints de cancer. La myostatine (Mstn) régule négativement la masse musculaire. Bien que la régulation des mécanismes moléculaires impliqués dans le contrôle de la masse musculaire joue un rôle central dans la cachexie associée au cancer, les relations existant entre la Mstn et les mécanismes physiopathologiques restent largement inconnues. Suite à l’inoculation de cellules Lewis lung carcinoma (LLC) à des souris, nous avons montré que l’invalidation du gène de la Mstn (souris Mstn-/-) confère une résistance au développement de la cachexie associée au cancer par rapport à des souris sauvages. La déficience en Mstn prévient la perte de masse musculaire et réduit la croissance tumorale, 35 jours après l’injection des cellules LLC, et est associée à un allongement de la durée de vie des souris. L’invalidation du gène de la Mstn provoque aussi une augmentation de l’apoptose des cellules LLC et une diminution de l'expression de gènes impliqués dans la prolifération et le métabolisme tumoraux. L’activation des systèmes protéolytiques ubiquitine-protéasome et autophagie-lysosome, due au développement tumoral, est réduite voire supprimée dans le muscle des souris Mstn-/-. L’accumulation de céramides intramusculaires, un sphingolipide formé suite à une lipolyse exacerbée, est corrélée à la perte de masse musculaire, suggérant que les céramides pourraient être un médiateur cellulaire impliqué dans la cachexie associée au cancer. Ces résultats montrent que la Mstn joue un rôle essentiel dans la cachexie associée au cancer / Cachexia is a complex clinical and metabolic syndrome, whose definition is imprecise, characterized by an uncontrolled loss of adipose tissue and skeletal muscle mass, frequently observed in cancer patients, and leading to death in 25% of cancer patients. Myostatin (Mstn) is a negative regulator of skeletal muscle mass and a critical determinant of skeletal muscle homeostasis. Although the regulation of the molecular mechanisms involved in the control of skeletal muscle mass plays a central role in the pathogenesis of cancer cachexia, the relationships between Mstn and the pathophysiological mechanisms remain largely unknown. Following subcutaneous inoculation of Lewis lung carcinoma cells (LLC) in mice, we showed that the Mstn gene inactivation (Mstn-/- mice) confers resistance to the development of cancer cachexia, compared to wild type mice. Mstn deficiency prevents the loss of skeletal muscle mass and reduces tumor growth, 35 days after the inoculation of LLC cells, and this is associated with a longer life of mice. Mstn gene inactivation also causes an increased apoptosis of LLC cells and decreases expression of genes involved in tumor proliferation and metabolism. Activation of ubiquitin-proteasome and autophagy-lysosome proteolytic systems, triggered by tumor growth is significantly reduced or suppressed in skeletal muscle of Mstn-/- mice. Accumulation of intramuscular ceramides, a sphingolipid synthesized due to excessive lipolysis, is correlated with the loss of muscle mass, suggesting that ceramides may be a cellular mediator involved in the pathogenesis of cancer cachexia. These results show that Mstn plays a critical role in the pathogenesis of cancer cachexia

A produção de aves no Brasil vem crescendo na ordem de 10% a cada ano, o que se explica pela atualização constante da tecnologia do setor (http://www.abef.com.br). Sendo a carne de frango a fonte de proteína animal mais barata e acessível ao consumidor, há necessidade de se produzir cada vez mais animais com maior acúmulo de massa muscular. Para isso, o entendimento dos mecanismos celulares e moleculares envolvidos na formação da musculatura esquelética é de extrema relevância. Os fatores miogênicos, genes responsáveis pela determinação e diferenciação de células musculares, foram clonados e progressos significativos foram desenvolvidos quanto ao controle da expressão dos mesmos. A utilização da técnica de seqüenciamento de DNA possibilita a identificação e caracterização de novos genes envolvidos na complexa rede de fatores que regulam a formação da musculatura esquelética em aves. Neste estudo, foram construídas duas bibliotecas de cDNA (fase embrionária e pós-eclosão) de músculo peitoral de uma linhagem de corte (TT) e uma biblioteca da fase embrionária de uma linhagem de postura (CC). A análise das seqüências EST (Expressed Sequence Tags) foi utilizada para identificar possíveis novos genes envolvidos no processo de formação da musculatura esquelética. As seqüências EST identificadas possibilitaram a construção de um banco com 6247 ESTs da musculatura peitoral das linhagens de corte e postura nas duas fases de desenvolvimento. Com o intuito de estabelecer uma relação entre o perfil de expressão dos fatores miogênicos: MyoD, MRF4 e miogenina; e dos genes Pax-3 e miostatina e a formação e maturação das fibras musculares, foi utilizada a técnica de PCR em tempo real. Em geral, a expressão dos fatores miogênicos foi maior na linhagem de corte em relação à de postura nas idades estudadas. Este estudo deverá contribuir para as áreas celular e molecular de desenvolvimento, além de fornecer recursos úteis aos programas de melhoramento genético de aves que visam obter animais com maior acúmulo de massa muscular. / Brazilian’s chicken production is increasing annually around 10%, which can be explained by the current technology applied to this sector (http://www.abef.com.br). Being chicken’s meat the cheapest animal protein source for consumers, there is a need to produce even more animals with increased muscular mass. For this purpose, understanding the molecular and cellular mechanisms involved with the skeletal muscle development is of great relevance. The myogenic factors, genes responsible for the determination and differentiation of muscle cells, were cloned and significant progress was made on the control of their expression. The use of DNA sequencing technique allows the identification and characterization of new genes involved in the complex chain of factors signalling systems that regulates the expression of avian skeletal muscles. In this study, two cDNA libraries (embryonic and post-hatching phases) were constructed from the breast muscle of a chicken broiler line (TT) and one library, from the embryonic phase, from a chicken layer line (CC). The EST (Expressed Sequencing Tags) analysis was used to identify probable new genes involved in the skeletal muscle development. The identified ESTs were used to generate a database containing 6247 breast muscle ESTs from two chicken lines in two development phases. Real time PCR was employed with the aim of establishing a relationship among the expression profile of myogenic factors (MyoD, MFR4, and myogenin), Pax-3 and myostatin genes with the formation and maturation of muscle fibers. In general, the expression of myogenic factors was greater in the broiler than in the layer chicken line in the phases under study. These results should contribute to other cellular and molecular development studies besides providing useful resources for chicken breeding programs whose objective is the deposition of skeletal muscle mass.

Det har forskats mycket på olika signalvägar i det mänskliga genomet, trotts detta finns det många frågetecken som kvarstår. Denna uppsats undersöker några av dem. Syfte: Undersöka förändringar i genuttryck och mRNA-nivåer för hypertrofi- (MRF4) translations- (5.8S &amp; 18S) och proteolysreglerande gener (MuRF1 &amp; GDF-8) efter en 10 veckor lång styrketräningsperiod hos kvinnor och män. Frågeställningar: (1) Finns det en förändring i total mängd RNA före och efter en 10 veckors styrketräningsintervention. (2) Finns det en förändring i uttryck av MRF4, 5.8S, 18S, MuRF1 samt GDF-8 efter en 10 veckors styrketräningsintervention. (3) Finns det en könsskillnad i förändringen av total mängd RNA samt aktivering av MRF4, 5.8S, 18S, MuRF1 och GDF-8 efter en 10 veckors styrketräningsintervention. Metod: Urvalet för analysen bestod av 16 otränade försökspersoner varav 8 var män och 8 var kvinnor. Försökspersonerna utförde unilateral styrketräning av nedre extremiteten under 10 veckor, under 2 av dessa veckor utfördes ocklusionsträning.  Träningsperiodiseringen var vågformig (70-90% av 1RM, 5-12 rep, 3 ggr/vecka). Muskelbiopsier togs i det arbetande benet före träningsperiodens start samt 3-7 dagar efter träningsperiodens avslut. Genuttryck analyserades med qPCR. Resultat: Det fanns ingen signifikant skillnad i förändring mellan män och kvinnors totala RNA eller genuttryck. Total RNA ökade signifikant (p&lt;0,01) med 19,2 %. Kvinnorna hade en signifikant ökning (P&lt;0,05) av RNA på 27,6 % medan männen hade en signifikant ökning (p&lt;0,05) på 14 %. MRF4 hade en signifikant (P&gt;0,05) procentuell ökning i genuttryck med 55,7 % och kvinnor för sig hade en signifikant (P&gt;0,05) ökning på 64 %. GDF-8 ökade signifikant (P&gt;0,05) med 55,5 % medan GAPDH ökade signifikant (P&gt;0,05) för båda könen tillsammans med 70,6 % och för män med 87,8 %. MuRF1 och 5.8S hade inga signifikanta förändringar i genuttryck. Slutsats: Det verkar som att både män och kvinnor får en liknande procentuell förändring av total RNA och mRNA genuttryck 3-7 dagar efter en 10 veckors hypertrofistyrd styrketräningsperiod. För att mäta genuttryck av translationsgenen MRF4 verkar 3-7 dagar efter en 10 veckors styrketräningsperiod vara en tidpunkt då det fortfarande pågår hypertrofi av skelettmuskulaturen.  Av de proteolysreglerande generna GDF-8 och MuRF1 sågs en uppreglering av GDF-8 vilket skulle kunna vara ett tecken på att hypertrofin börjar hämmas. Ett oväntat fynd var att GAPDH visade sig vara olämplig som kontrollgen vid en styrketräningsintervention på 10 veckor och att 18S var väldigt stabil. Detta kan betyda att GAPDH inte skall användas vid längre styrketräningsinterventioner. / There have been much research on signaling pathways in the human genome, but there still remain many questions. This paper examines some of them. Aim: Investigate changes in gene expression and mRNA levels of hypertrophy (MRF4), translation (5.8S &amp; 18S) and proteolysis regulating genes (GDF-8) after a 10-week strength training period in men and women. Research questions: (1) Is there a change in the total amount of RNA before and after a 10-week strength training intervention. (2) Is there a change in the expression of MRF4, 5.8S, 18S, Murf1 and GDF-8 after 10 weeks of strength training. (3) Is there a gender difference in the change of total RNA and the expression of MRF4, 5.8S, Murf1 and GDF-8 after a 10-week long strength training intervention. Method: The sample for analysis consisted of 16 untrained subjects, of whom 8 were men and 8 were women. The subjects performed unilateral resistance training of lower extremities for 10 weeks, during two of these weeks blood flow restriction training were performed. The training was undulating (70-90% of 1RM, 5-12 cord, 3 times / week). Muscle biopsies were taken from the working leg before the start and 3-7 days after the training period. Gene expression was analyzed by qPCR. Results: There was no significant gender difference in total RNA or gene expression. Total RNA was significantly increased (p &lt;0.01) with 19.2 %. The women had a significant increase (P &lt;0.05) of RNA at 27.6 %, while the men had a significant increase (p &lt;0.05) at 14 %. MRF4 had a significant (P&gt; 0.05) percentage increase in gene expression by 55.7 %, and women had a significant (P&gt; 0.05) increase of 64 %. GDF-8 increased significantly (P&gt; 0.05) with 55.5 %, while GAPDH increased significantly (P&gt; 0.05) for both sexes with 70.6 % and for men with 87.8 %. Murf1 and 5.8S had no significant changes in gene expression. Conclusions: It seems that both men and women experience a similar percentage difference of total RNA and mRNA gene expression 3-7 days after a 10 weeks long strength training period. To measure the gene expression of MRF4 3-7 days after a 10-week weight-training period seems to be a time when there still is a anabolic responses in the skeletal muscle. Of the proteolysis regulating genes GDF-8 and Murf1 there was an upregulation of GDF-8, which could be a sign that the inhibition of hypertrophy started. An unexpected finding is that GAPDH was found to be unsuitable as a control gene at a strength training intervention at 10 weeks and rRNA 18S was very stable, which could mean that GAPDH should not be used as control gene in longer strength training studies.

Orientador: Maeli Dal Pai Silva / Tese ( doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-18T12:24:51Z (GMT). No. of bitstreams: 1 Carani_FernandaRegina_D.pdf: 24872848 bytes, checksum: e4b7c794fa866be614e932ec5a33eaf6 (MD5) Previous issue date: 2011 / Resumo: O pirarucu (Arapaima gigas) caracteriza-se como uma espécie promissora para a Aqüicultura, devido principalmente às suas características de rápido crescimento e rusticidade. Sua criação em regime intensivo tem obtido enorme sucesso, podendo alcançar até 10 quilos de peso corporal em apenas um ano de criação. O pirarucu é considerado hoje uma das mais importantes espécies de peixes da bacia Amazônica e, por esta razão, é primordial que se investigue os mecanismos celulares e moleculares que controlam o rápido crescimento muscular, contribuindo com novas estratégias de criação e com a manutenção da espécie. O crescimento do músculo estriado esquelético nos peixes pode ocorrer por dois mecanismos: hipertrofia e/ou hiperplasia das fibras, a partir de células satélites ou mioblastos. Esse processo é controlado por Fatores Reguladores Miogênicos (MRFs) e pelo fator de crescimento Miostatina. O objetivo do presente estudo foi avaliar as características morfológicas e o crescimento muscular hipertrófico e hiperplásico, bem como analisar a expressão gênica e protéica da MyoD, da Miogenina e da Miostatina na musculatura esquelética do pirarucu (A. gigas), em diferentes fases de crescimento. Os animais utilizados no presente estudo foram provenientes de duas pisciculturas: na primeira, foram obtidos os "alevinos" (pós-larvas; 48 g); na segunda, os animais em diferentes estágios de crescimento, divididos em quatro grupos de acordo com o peso corporal. Grupo A (50 gramas, n=7), grupo B (420 gramas, n=7), grupo C (5,5 quilogramas, n=7) e grupo D (9,1 quilogramas, n=7). As amostras musculares foram coletadas, congeladas e submetidas à coloração HE, para avaliação do padrão morfológico das fibras, e à reação para a enzima NADH-TR, para avaliar o metabolismo oxidativo das fibras. Para avaliar o padrão de crescimento hiperplásico e hipertrófico da musculatura branca, foi calculado o menor diâmetro de uma população de fibras por animal, e estas foram distribuídas em classes, na dependência do seu diâmetro. A análise da expressão gênica de MyoD, miogenina e miostatina foi feita por Reação em Cadeia da Polimerase após Transcrição Reversa (RTqPCR); para análise da expressão protéica, foi utilizado o Western Blot. A distribuição das fibras em classes de diâmetro exibiu o seguinte padrão: o grupo A mostrou a maior parte das fibras na classe 20, o grupo B, na classe 50, o grupo C, nas classes 50 e 80, e o grupo D, na classe 80. Isso indica uma alta taxa de hiperplasia das fibras nos grupos menores (A e B) e alta hipertrofia das fibras nos grupos maiores (C e D). Para a análise da expressão gênica de MyoD e miogenina no músculo vermelho e branco dos "alevinos", não houve diferença estatística; para a miostatina, houve expressão diferencial, com os maiores níveis encontrados no músculo branco em comparação com o músculo vermelho. Na avaliação da expressão de MyoD e miogenina, tanto a expressão gênica como a expressão protéica não mostraram diferença significativa. Por outro lado, a expressão gênica da miostatina foi menor no grupo A e maior nos demais, e a expressão da proteína miostatina foi maior no grupo A, diminuindo nos demais grupos. Estes resultados refletem as características de crescimento muscular da espécie e sugerem que a expressão dos MRFs e da miostatina são responsáveis pelo balanço entre a hiperplasia e a hipertrofia das fibras, contribuindo para o rápido crescimento da espécie e a manutenção das características do filé / Abstract: Pirarucu (Arapaima gigas) is a promising fish species for Aquaculture programs mainly by the fast growing feature and rusticity. Their rearing under intensive conditions generated much successful results, as they reach up to 10 kilograms in just one year. Considered one of the most important fish species from Amazon basin, it is of primary interest to investigate the cellular and molecular mechanisms that control the fast muscle growth in pirarucu, providing information for new rearing strategies and species conservation. In most fish, skeletal muscle growth occurs by two mechanisms: hypertrophy and hyperplasia, from satellite cells or myoblasts. These process are under control by Myogenic Regulatory Factors (MRFs) and by the growth factor Myostatin. The animals were obtained from two pisciculture, where we got the alevin pirarucu (n=7; 48 grams weight), and the specimens at different growth stages, divided into groups according body weight. Group A (50 grams, n=7), group B (420 grams, n=7), group C (5,5 kilograms, n=7) and group D (9,1 kilograms, n=7). Muscle samples were collected, frozen and stained with HE for morphological analysis, and submitted to NADH-TR enzyme reaction for oxidative methabolism analysis. To evaluate hyperplasic and hypertrophic muscle growth, it was measured the smallest diameter from a set of fibers, which were grouped into diameter classes. Gene expression analysis of MyoD, Myogenin and Myostatin were performed by Quantitative Polimerase Chain Reaction after Reverse Transcription (RT-qPCR); protein content analysis was by Western Blot technique. Muscle fibers distribution in classes showed the following pattern: group A showed most fibers in class 20, group B, in class 50, group C, in classes 50 and 80, and group D, in class 80. This is an indicative of high fiber hiperplasia rate in groups A and B, and high hypertrophy in groups C and D. There was no statistical difference in MyoD and Myogenin genes expression in red and white muscles of pirarucu; however, Myostatin expression showed high levels in white muscle compared to red muscle. Evaluating MyoD and Myogenin expression in white muscle of pirarucu at different growth stages, both gene and protein levels were similar. Myostatin gene expression was low in group A and high in the other groups; on the other hand, Myostatin protein was high in group A and low in the other groups. These results reflect the muscle growth characteristics in pirarucu and suggest that the MRFs and Myostatin expression are controlling the balance between hyperplasic and hypertrophic mechanisms, promoting the fast rate feature of pirarucu and their fillet quality / Doutorado / Biologia Celular / Doutor em Biologia Celular e Estrutural